Clinipace Worldwide announces acquisition of PFC

Clinipace Worldwide, a global digital clinical research organization (dCRO), and Swiss-based PFC Pharma Focus (PFC) today jointly announced a definitive merger agreement under which Clinipace Worldwide has acquired all outstanding shares of privately-held PFC and its subsidiaries. Based in Zurich, Switzerland - with offices in Germany, Israel and India - PFC is a pan-European contract research provider focused on drug and medical device development services and regulatory consulting.

The combination of PFC and Clinipace Worldwide creates a truly global dCRO with centralized North American, South American, and European hubs for strategic drug and medical device product development, clinical operations, data management, regulatory affairs, and GxP/CMC quality assurance. The companies share a collective vision of helping emerging and mid-tier life science firms clients serve patients by substantially accelerating the drug and device development processes via technology-amplified services. Clinipace is strongly differentiated in the marketplace through its proprietary technology -based dCRO value proposition which gives clients more control over timelines and resources, enhanced project visibility, reduced cost, and improved risk mitigation.

"With this acquisition, our third in the past 18 months, we have assembled the right global footprint and the right mix of global therapeutic expertise, strategic product development assets and operational capabilities to uniquely meet the needs of our clients," commented Jeff Williams, CEO and Chairman, Clinipace Worldwide. "Together with the PFC team we're better positioned to serve the needs of our clients by quickly and efficiently scaling to support their global phase 2-3 trials across a number of therapeutic areas and indications."

"This is a great win for our client base as they now have access to Clinipace's extensive experience and capabilities in conducting trials and providing regulatory consulting across North and South America; as well as their proven technology (TEMPO™ eClinical platform)," said Kurt Pfister, CEO, European Operations, Clinipace Worldwide (former CEO, PFC Pharma Focus, Ltd.)

PFC was co-founded in 1992 by Kurt Pfister, PhD, and Kathryn Voegeli, PhD, and brings twenty years of broad multi-therapeutic experience to Clinipace Worldwide. Kurt and Kathryn join the executive team as CEO of European Operations and COO of European Operations, respectively. Jeff Williams will remain the Chief Executive Officer and Chairman of the combined company.

"Together we can make real gains in overcoming the gaps in process that make traditional CROs inefficient," said Chris Porter, COO, Clinipace Worldwide. "We share a long-term strategy of creating a more efficient and effective technology-amplified solution for our life sciences clients around the world."